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Abstract
Involvement of para-aortic nodes (PAN) has been detected at pathological examination in 10–25% of locally advanced gastric 
cancer. Based on these data of nodal diffusion, the lymphadenectomy of para-aortic stations would be desirable in locally 
advanced gastric cancer. However, the debate on the oncological benefit of para-aortic nodes dissection is still not solved. A 
review of the literature was performed and papers reporting either the rate of para-aortic nodal metastases or the long-term 
survival outcomes after D2+ para-aortic nodes dissection (PAND) or D3 lymphadenectomy were descriptively reported. 
The literature survey yielded 14 studies. Most of the papers show the outcome of series of advanced gastric cancer treated 
with surgery alone, while starting from 2012, 3 articles report the outcomes of D2 + PAND or D3 lymphadenectomy after 
preoperative chemotherapy. The rate of PAN metastases ranges between 8.5 and 28% in surgical series. Survival outcomes 
largely improved in series of patients treated with multimodal approach compared to those of surgery alone. In patients with 
clinically detected para-aortic nodal metastases, preoperative chemotherapy followed by PAND is indicated. More data are 
needed to clarify the indication to prophylactic PAND in the era of multimodal treatment, anyway super-extended lymphad-
enectomies have to be performed by experienced surgeons in dedicated centres.
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Introduction
Despite the declining incidence and the therapeutic improve-
ments achieved in the last decades, gastric cancer (GC) is 
still a major cause of cancer death worldwide [1]. Therefore, 
further improvements in treatment through more tailored 
strategies are essential.
Surgery remains the cornerstone of curative intent ther-
apy. As such, the extent of surgical resection, especially the 
extent of lymphadenectomy, is one of the key elements that 
needs to be personalized according to patients and tumours 
characteristics to get the best outcome for each patient by 
balancing post-operative complications and oncological 
benefits.
Involvement of para-aortic nodes (PAN) has been 
detected at pathological examination in 10–25% of locally 
advanced GCs [2, 3] when considering also the incidence of 
micrometastases, Natsugoe et al. reported a positivity rate 
up to 64% [4].
Based on the data of nodal diffusion, the lymphadenec-
tomy of para-aortic stations would be desirable in locally 
advanced gastric cancer. However, the debate on the onco-
logical benefit of para-aortic nodes dissection is still not 
solved. Indeed, on the other hand, para-aortic nodal involve-
ment is considered as expression of a metastatic disease both 
by the 8th edition of TNM staging [5] and the 3rd Japanese 
Classification of gastric cancer [6], while on the other hand 
some authors [7], suggest considering the cases of gastric 
cancer harbouring metastases to the para-aortic nodes as 
borderline resectable rather than metastatic tumours as the 
long-term outcomes observed in such patients are much 
more better compared with other metastatic tumours [8]. 
In the present review, based on the available literature data, 
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we will describe the current indications to para-aortic nodal 
dissection as well as the open questions on this topic.
Methods
VM searched PubMed for papers using the key words “para-
aortic” AND “gastric cancer” AND “lymphadenectomy”. 
Only studies in English language reporting either the rate 
of para-aortic nodal metastases or the long-term survival 
outcomes after D2+ PAND or D3 lymphadenectomy were 
included. Results of literature review were descriptively 
reported.
Results
The literature survey yielded 14 studies [9] (Table 1). Most 
of the papers show the outcome of series of advanced gastric 
cancer treated with surgery alone [9], while starting from 
2012, 3 articles report the outcomes of D2+ para-aortic or 
D3 lymphadenectomy after preoperative chemotherapy [20]. 
The rate of PAN metastases ranges between 8.5 and 26.1% 
in surgical series where no selection of patients based on 
tumour site was made [11]. The rate of PAN metastases was 
28% in a surgical series including only upper third tumours 
[9]. Survival outcomes largely improved in series of patients 
treated with multimodal approach compared to those with 
surgery alone (Table 1).
Discussion
History of para‑aortic nodal dissection in gastric 
cancer
D2 lymphadenectomy is the standard of care in Japan and 
South Korea since decades [23, 24], more recently also in 
Europe the guidelines recommend the extended D2 dissec-
tion in case of curative intent treatment of GC [25–28].
The benefit of further extending the lymphadenectomy 
beyond the D2 is controversial.
Table 1  Main studies (in English language) that reported data on para-aortic nodes dissection, involvement rate and long-term outcomes in 
patients with pathological positivity of PAN (pPAN+) after super-extended dissection
a The survival is reported as cancer-related 5-year survival probability (± standard error)
b Only tumours with duodenal invasion
c Only upper third tumours
d Only prophylactic PAND
e Only patients with pathologically positive para-aortic nodes
f Only patients with clinically positive para-aortic lymph nodes
NB 2-year OS
Author/year N patients underwent 
D2 + PAND or D3 
 lymphadenectomyb
% neoadjuvant % pathologi-
cally positive 
PAN
5-year OS of all 
D2+ PAND/cohort, 
(%)
5-year OS of pPAN+ 
patients
Baba et al. 2000 [9] 75c 0 28 NA NA
Kunisaki et al. 2006 [10] 150 0 NA 54 –
Sasako et al. 2008 [11] 260d 0 8.5 54.9 18.5%
Yonemura et al. 2008 [12] 134 0 9.0 55 25%
Fujimura et al. 2009 [13] 222 0 24.7 – 22%
Roviello et al. 2010 [14] 286 0 12.9 52 17%
Tokunaga et al. 2010 [15] 178e 0 100 – 13–28.6% if ≤15 positive 
nodes, no macroscopic 
type 4
De Manzoni et al. 2015 [16] 294 0 11.6 NA NA
Morita et al. 2016 [17] 232 0 14.2 61 21.2%
Marrelli et al. 2017 [18] 390 0 10.8 – 11 ± 5%a
Kumagai et al. 2017 [19] 23 (16 a2)b
20 (16 b1)b
NA 25 (16 a2)
26.1 (16 b1)
– 50.0% (16 a2)
40.0% (16 b1)
Oyama et al. 2012 [20] 44e 36 100 – 32.9% (no preop CT)NB
93.8% (after preop CT)NB
Tsuburaya et al. 2014 [21] 51 100 – 53 57% (if no bulky N2)
Fujiwara et al. 2015 [22] 20f 100 40 65 –
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The para-aortic area is considered as the outmost nodal 
station before the systemic lymphatic flow. Based on this con-
sideration and according to retrospective data reporting a high 
rate (10–30%) of PAN pathological involvement [29], D2+ 
para-aortic nodal dissection (PAND) or super-extended D3 
lymphadenectomy have been routinely performed for advanced 
gastric cancer in Japan as well as in dedicated Western centres 
in the past decades.
Both Eastern and European authors reported satisfying 
long-term outcomes in patients with pathological positivity 
of PAN (pPAN+) after super-extended dissection (Table 1). 
Tokunaga et al. showed that in pPAN+ patients, if exclud-
ing cases with linitis plastica or with more than 15 positive 
lymph nodes, 5-year overall survival was 28.6% after D3 dis-
section [15]. Similarly, in a study of the Italian Research Group 
for Gastric Cancer (GIRCG), the 5-year overall survival in 
pPAN+ after D3 lymphadenectomy was 17% [30].
However, since the publication of the Japan Clinical Oncol-
ogy Group (JCOG) 9501 trial [11], showing no survival ben-
efit of prophylactic D2+ PAND compared to D2 lymphadenec-
tomy alone in advanced gastric cancer, the routine PAND is 
no more indicated.
Of note, that trial excluded cases with clinically detected 
PAN metastases, leading to a lower rate of PAN metastases 
retrieved at pathological examination (8.5%) compared to 
previous studies. Nevertheless, Sasako et al. reported a not 
negligible 5-year overall survival rate of 18.2% in patients with 
PAN metastases after prophylactic PAN dissection. Moreover, 
that trial [11], although not finding any significant survival 
advantage after PAN dissection with respect to simple D2 in 
the whole sample, highlighted significant interactions between 
T or N status and extension of lymphadenectomy (p = 0.004 
and p = 0.003, respectively): paradoxically, patients with less 
advanced cancer (subserosal and node-negative tumours) 
showed a significant benefit from PAN dissection.
Taken together, these considerations suggest the possibil-
ity that the D2+ PAND can offer a chance of cure in selected 
patients with advanced GC without clinically detectable 
PAN metastases [31].
All the above-mentioned evidences suggest the need 
of further investigations on the role of PAN dissection in 
advanced GC, especially if considering the increasing effi-
cacy of chemotherapy regimens either in neo-adjuvant or in 
metastatic setting.
Both, the role of PAND in patients with clinically positive 
PAN and the role of prophylactic PAND should be reconsid-
ered in the era of multimodal treatment.
Para‑aortic nodal dissection in the era 
of multimodal treatment
Interesting findings arise from recent studies explor-
ing the role of para-aortic dissection after preoperative 
chemotherapy [20–22] (Table 1). A phase II Japanese 
trial demonstrated that in patients with clinically detected 
extensive nodal metastases (bulky nodes in the D2 sta-
tions) with or without lymphadenopathy in the para-aor-
tic (No. 16 a2–b1) regions, a multidisciplinary treatment 
including two courses of neo-adjuvant chemotherapy with 
S-1+ cisplatin followed by D2 plus PAND lead to a 5-year 
survival rate of 53% [21].
Specifically, in patients with clinically bulky nodes in 
the second-level perigastric stations without preoperative 
evidence of PAN metastases, the 5-year overall survival 
was 68%, while in patients with clinically detected PAN 
metastases without bulky N2 nodes, the 5-year overall sur-
vival was 57%, while in patients with both initial bulky N2 
and PAN metastases the 5-year overall survival was 17%.
Interestingly, only 15 (31%) of patients included in the 
trial were pathologically staged as pN3, including PAN 
metastases: according to the clinical node status in 48 eli-
gible patients who underwent surgery, pN3 disease was 
found in 5 of 24 patients with bulky N2 disease only, 4 of 
14 with bulky PAN involvement alone, and 5 of 10 with 
both bulky N2 and PAN-positive tumours.
Of note, in that trial, peritoneal metastasis as well as the 
peritoneal cytology status had to be ruled out by staging 
laparoscopy prior to registration. The results of this Japanese 
trial are very relevant and confirm that in the era of multi-
modal treatment the role of PAN dissection is beneficial in 
patients with clinically detected PAN metastases after chem-
otherapy unless peritoneal cytology or peritoneal metasta-
ses are detected at staging laparoscopy. But also a role of 
“prophylactic” PAND after preoperative chemotherapy in 
locally advanced gastric cancer is suggested. In this case, the 
prophylactic PAND after chemotherapy was demonstrated 
highly beneficial (5-year OS 68%) in patients with bulky 
N2, i.e., one node ≥ 3 cm or two adjacent nodes ≥ 1.5 cm in 
the second-level perigastric stations. Moreover, also other 
patients with locally advanced gastric cancer may benefit 
from the prophylactic extension of lymphadenectomy to the 
para-aortic area. Indeed, a recent Korean study, by analysing 
2618 patients who had undergone gastrectomy with D2 lym-
phadenectomy for gastric cancer very rarely (1.3% of cases) 
extended to PAN [32], reported a loco-regional relapse rate 
of 8.5% 5 years after surgery, this was most often seen out-
side the D2 dissected area (90,4%) in particular in the sta-
tions 16 a2 and 16 b1 (46 and 60%, respectively). These 
findings further support the hypothesis that some subgroups 
of patients with advanced gastric cancer have PAN microme-
tastases or metastases that are not detectable trough the cur-
rent available preoperative imaging examinations. It could 
be hypothesized that prophylactic PAND would prevent 
loco-regional relapse in these patients, especially if there 
is a good clinical response to preoperative chemotherapy.
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How to select patients for prophylactic PAND 
in the era of multimodal treatment?
Based on the consideration that patients with clinically 
detectable PAN metastases treated with preoperative chem-
otherapy followed by PAND have a good prognosis [21], 
the same treatment option should not be denied to those 
patients who have clinically negative but pathological posi-
tive PAN. Indeed, even if a good accuracy of CT scan has 
been reported both by Eastern and Western authors [33, 34] 
in some cases of locally advanced gastric cancer with dif-
fuse histotype, pathological nodal metastases were found 
also in clinically negative cases. Moreover, as stated above, 
the possible role of PAND on preventing cancer relapse by 
blocking lymphatic channels from the stomach or removing 
PAN micrometastases, is basically unknown.
Of course, the problem is how to identify the patients 
with locally advanced gastric cancer at high risk of PAN 
metastases [18] that may benefit from PAND.
Interestingly, in a previous study by our group, by analys-
ing a series of patients with advanced gastric cancer includ-
ing those with PAN metastases, we found that the rate of 
loco-regional relapse was comparable after D2 or D3 lym-
phadenectomy (16.4% vs. 17%) in the whole series. How-
ever, we found a significantly higher risk of locoregional 
recurrence in the diffuse histotype after D2 compared with 
D3 [16]. It is likely that a more extended lymphadenectomy 
had played a better local control of those tumours that have 
a higher lymphotropism, and both patients with clinical posi-
tive PAN and those with pathological positive, but clinical 
negative PAN or with PAN micrometastasis could have ben-
efit from D3.
Considering the high proportion of Laurèn diffuse type 
especially of signet ring cell tumours that is currently 
observed in the West [35], the benefit of prophylactic PAND 
need to be evaluated through a dedicated trial comparing D2 
versus D2+ PAND or D3 in tumours with Laurèn diffuse/
WHO poorly cohesive and SRC tumours after neo-adjuvant 
chemotherapy.
Of course, the possible oncological benefit of super-
extended lymphadenectomy should be balanced with the risk 
of post-operative complications and mortality. Therefore, 
super-extended lymphadenectomies should be performed in 
dedicated high-volume hospitals.
Conclusion
In patients with clinically detected para-aortic nodal metas-
tases, preoperative chemotherapy followed by PAND is 
indicated. Prophylactic PAND after neo-adjuvant treat-
ment could also be of benefit in some subgroups of locally 
advanced gastric cancer at high risk of PAN metastases such 
as cases with bulky nodes in the second level perigastric 
nodal stations or with Laurèn diffuse/WHO poorly cohe-
sive and SRC tumours. More data are needed to clarify the 
indication TP prophylactic PAND, anyway super-extended 
lymphadenectomies have to be performed by experienced 
surgeons in dedicated centres.
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